Picture of AbCellera Biologics logo

ABCL — AbCellera Biologics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

investment in Canada

(Adds co-investment breakdown in paragraph 2)
       May 24 (Reuters) - AbCellera Biologics  ABCL.O  said on
Wednesday it will make a C$701 million ($515.6 million)
co-investment with the governments of Canada and British
Columbia to strengthen capabilities for drug development,
manufacturing and clinical research in the country.
    Over the next eight years, the company will invest C$401
million in the project, and the governments of Canada and
British Columbia will contribute C$225 million and C$75 million,
respectively.
    The project is expected to create hundreds of new
high-skilled jobs at AbCellera.
    The company has previously partnered with Eli Lilly and Co
 LLY.N  to develop antibody therapies, including Lilly's
experimental antibody treatments for COVID-19.
    
 ($1 = 1.3596 Canadian dollars)

 (Reporting by Sriparna Roy in Bengaluru; Editing by Devika
Syamnath and Shounak Dasgupta)
 ((Sriparna.Roy@thomsonreuters.com))

Recent news on AbCellera Biologics

See all news